Aura Biosciences Seeks Shareholder Approval for 350M Share Increase, Enabling Significant Future Dilution
AURA sits 45% above its 52-week low of $4.73.
Summary
Aura Biosciences filed its definitive proxy statement, seeking shareholder approval to increase authorized common stock by 350 million shares, which could lead to over 380% potential dilution, and to amend its equity incentive plan.
Key Events · Corporate Governance and Compliance · AURA
-
Massive Authorized Share Increase Proposed
Shareholders will vote on increasing authorized common stock from 150 million to 500 million shares. This 350 million share increase represents a potential dilution of over 380% if fully utilized, providing significant headroom for future capital raises and other corporate purposes.
-
Equity Plan Amendment
The company also seeks approval to amend its 2021 Stock Option and Incentive Plan to include pre-funded warrants in the calculation for annual share reserve increases, which would slightly boost the number of shares available for equity compensation.
-
Special Shareholder Meeting Scheduled
A virtual Special Meeting of Stockholders is scheduled for August 5, 2026, to vote on these proposals. This definitive proxy statement follows a preliminary filing on June 17, 2026.
Analysis · AURA · Life Sciences
Aura Biosciences has filed its definitive proxy statement, seeking shareholder approval for two key proposals at a special meeting on August 5, 2026. The most significant proposal is to increase the authorized common stock from 150 million to 500 million shares. This 350 million share increase, if approved, would provide the company with substantial flexibility for future capital raises, strategic transactions, and equity compensation. Given the current outstanding shares of approximately 103.4 million, this represents a potential dilution of over 380% if all authorized shares were issued. This move follows a recent dilutive public offering in May 2026 and indicates a proactive strategy to ensure long-term financing options, but at the cost of substantial potential dilution for existing shareholders. The second proposal is to amend the 2021 Stock Option and Incentive Plan to include pre-funded warrants in the evergreen calculation for annual share reserve increases, which would slightly boost the number of shares available for equity compensation.
At the time of this filing, AURA was trading at $6.88 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $711.6M. The 52-week trading range was $4.73 to $9.54. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.